395 related articles for article (PubMed ID: 21124782)
21. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
23. Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids
Nörz D; Mullins CS; Smit DJ; Linnebacher M; Hagel G; Mirdogan A; Siekiera J; Ehm P; Izbicki JR; Block A; Thastrup O; Jücker M
Anticancer Res; 2021 May; 41(5):2257-2275. PubMed ID: 33952452
[TBL] [Abstract][Full Text] [Related]
24. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
[TBL] [Abstract][Full Text] [Related]
25. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Chang Q; Chen E; Hedley DW
Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
[TBL] [Abstract][Full Text] [Related]
26. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
27. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
Oncotarget; 2014 Jul; 5(13):4765-78. PubMed ID: 24946858
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
[TBL] [Abstract][Full Text] [Related]
29. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
30. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
[TBL] [Abstract][Full Text] [Related]
31. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
32. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
Davies BR; Logie A; McKay JS; Martin P; Steele S; Jenkins R; Cockerill M; Cartlidge S; Smith PD
Mol Cancer Ther; 2007 Aug; 6(8):2209-19. PubMed ID: 17699718
[TBL] [Abstract][Full Text] [Related]
33. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
35. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
36. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Holland WS; Chinn DC; Lara PN; Gandara DR; Mack PC
J Cancer Res Clin Oncol; 2015 Apr; 141(4):615-26. PubMed ID: 25323938
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
38. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
[TBL] [Abstract][Full Text] [Related]
39. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
Xu J; Knox JJ; Ibrahimov E; Chen E; Serra S; Tsao M; Cao P; Vines D; Green DE; Metran-Nascente C; McNamara MG; Hedley DW
Clin Cancer Res; 2013 Jan; 19(1):118-27. PubMed ID: 23091117
[TBL] [Abstract][Full Text] [Related]
40. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]